Your browser doesn't support javascript.
loading
Impact of individual level uncertainty of lung cancer polygenic risk score (PRS) on risk stratification.
Wang, Xinan; Zhang, Ziwei; Ding, Yi; Chen, Tony; Mucci, Lorelei; Albanes, Demetrios; Landi, Maria Teresa; Caporaso, Neil E; Lam, Stephen; Tardon, Adonina; Chen, Chu; Bojesen, Stig E; Johansson, Mattias; Risch, Angela; Bickeböller, Heike; Wichmann, H-Erich; Rennert, Gadi; Arnold, Susanne; Brennan, Paul; McKay, James D; Field, John K; Shete, Sanjay S; Le Marchand, Loic; Liu, Geoffrey; Andrew, Angeline S; Kiemeney, Lambertus A; Zienolddiny-Narui, Shan; Behndig, Annelie; Johansson, Mikael; Cox, Angie; Lazarus, Philip; Schabath, Matthew B; Aldrich, Melinda C; Hung, Rayjean J; Amos, Christopher I; Lin, Xihong; Christiani, David C.
Afiliación
  • Wang X; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, 667 Huntington Ave, Boston, MA, 02115, USA.
  • Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ding Y; Bioinformatics Interdepartmental Program, University of California, Los Angeles, USA.
  • Chen T; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
  • Mucci L; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
  • Albanes D; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Landi MT; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Caporaso NE; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Lam S; Department of Medicine, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada.
  • Tardon A; Faculty of Medicine, University of Oviedo and CIBERESP, Oviedo, Spain.
  • Chen C; Department of Epidemiology, University of Washington School of Public Health, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Bojesen SE; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
  • Johansson M; Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
  • Risch A; Department of Biosciences and Medical Biology, Allergy-Cancer-BioNano Research Centre, University of Salzburg, and Cancer Cluster Salzburg, Salzburg, Austria.
  • Bickeböller H; Department of Genetic Epidemiology, University Medical Center, Georg August University Göttingen, Göttingen, Germany.
  • Wichmann HE; Institute of Medical Informatics, Biometry and Epidemiology, Ludwig Maximilians University, Munich, Germany.
  • Rennert G; Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Carmel, Haifa, Israel.
  • Arnold S; Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
  • Brennan P; Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
  • McKay JD; Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
  • Field JK; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Shete SS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Le Marchand L; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
  • Liu G; Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
  • Andrew AS; Department of Epidemiology, Department of Community and Family Medicine, Dartmouth Geisel School of Medicine, Hanover, NH, USA.
  • Kiemeney LA; Department for Health Evidence, Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Zienolddiny-Narui S; National Institute of Occupational Health, Oslo, Norway.
  • Behndig A; Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
  • Johansson M; Department of Radiation Sciences, Umeå University, Umeå, Sweden.
  • Cox A; Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.
  • Lazarus P; Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA, USA.
  • Schabath MB; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Aldrich MC; Department of Medicine, Department of Biomedical Informatics and Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Hung RJ; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • Amos CI; Institute for Clinical and Translational Research, Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
  • Lin X; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
  • Christiani DC; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, 667 Huntington Ave, Boston, MA, 02115, USA. dchris@hsph.harvard.edu.
Genome Med ; 16(1): 22, 2024 02 05.
Article en En | MEDLINE | ID: mdl-38317189
ABSTRACT

BACKGROUND:

Although polygenic risk score (PRS) has emerged as a promising tool for predicting cancer risk from genome-wide association studies (GWAS), the individual-level accuracy of lung cancer PRS and the extent to which its impact on subsequent clinical applications remains largely unexplored.

METHODS:

Lung cancer PRSs and confidence/credible interval (CI) were constructed using two statistical approaches for each individual (1) the weighted sum of 16 GWAS-derived significant SNP loci and the CI through the bootstrapping method (PRS-16-CV) and (2) LDpred2 and the CI through posteriors sampling (PRS-Bayes), among 17,166 lung cancer cases and 12,894 controls with European ancestry from the International Lung Cancer Consortium. Individuals were classified into different genetic risk subgroups based on the relationship between their own PRS mean/PRS CI and the population level threshold.

RESULTS:

Considerable variances in PRS point estimates at the individual level were observed for both methods, with an average standard deviation (s.d.) of 0.12 for PRS-16-CV and a much larger s.d. of 0.88 for PRS-Bayes. Using PRS-16-CV, only 25.0% of individuals with PRS point estimates in the lowest decile of PRS and 16.8% in the highest decile have their entire 95% CI fully contained in the lowest and highest decile, respectively, while PRS-Bayes was unable to find any eligible individuals. Only 19% of the individuals were concordantly identified as having high genetic risk (> 90th percentile) using the two PRS estimators. An increased relative risk of lung cancer comparing the highest PRS percentile to the lowest was observed when taking the CI into account (OR = 2.73, 95% CI 2.12-3.50, P-value = 4.13 × 10-15) compared to using PRS-16-CV mean (OR = 2.23, 95% CI 1.99-2.49, P-value = 5.70 × 10-46). Improved risk prediction performance with higher AUC was consistently observed in individuals identified by PRS-16-CV CI, and the best performance was achieved by incorporating age, gender, and detailed smoking pack-years (AUC 0.73, 95% CI = 0.72-0.74).

CONCLUSIONS:

Lung cancer PRS estimates using different methods have modest correlations at the individual level, highlighting the importance of considering individual-level uncertainty when evaluating the practical utility of PRS.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Puntuación de Riesgo Genético / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Genome Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Puntuación de Riesgo Genético / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Genome Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos